Trial Profile
A study of cetuximab as a third line treatment of metastatic colorectal carcinoma (mCRC), in patients with wild type K-ras gene
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Oct 2015
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Irinotecan
- Indications Colon cancer
- Focus Therapeutic Use
- 06 Oct 2015 New trial record